A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases

Clinical Genitourinary Cancer

Volumn 12, Issue 1, 2014, Pages 50-54

  Chevreau, Christine ^a   Ravaud, Alain ^b   Escudier, Bernard ^c   Amela, Eric ^d   Delva, Remy ^e   Rolland, Frederic ^e   Tosi, Diego ^f   Oudard, Stephane ^g   Blanc, Ellen ^h   Ferlay, Celine ^h   Négrier, Sylvie ^h,i  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e Institut de Cancérologie de l'Ouest ^*  (France)

^f CENTRE VAL D AURELLE   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ UNIVERSITÉ DE LYON   (France)

Author keywords

Brain metastases; Clinical trial; Renal cell carcinoma; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; ARTICLE; ASTHENIA; BRAIN METASTASIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG EMBOLISM; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PERITONITIS; PHASE 2 CLINICAL TRIAL; SEPTIC SHOCK; STOMACH PERFORATION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

BRAIN METASTASES; CLINICAL TRIAL; RENAL CELL CARCINOMA; SUNITINIB;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; SURVIVAL; TREATMENT OUTCOME;

EID: 84892434422     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.09.008     Document Type: Article

References (11)

1. J. Remon, P. Lianes, and S. Martínez Brain metastases from renal cell carcinoma. Should we change the current standard? Cancer Treat Rev 38 2012 249 257
2. M. Bianchi, M. Sun, and C. Jeldres et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis Ann Oncol 23 2012 973 980
3. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma New Eng J Med 356 2007 115 124
4. NCCN Kidney Cancer Guidelines v2. 2012. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed September 17, 2012.
5. C. Massard, J. Zonierek, and M. Gross-Goupil et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib Ann Oncol 21 2010 1027 1031
6. Henderson CA, Bukowski RM, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: subset analysis of patients with brain metastases (abstract). J Clin Oncol 2007; ASCO Annual Meeting; 25(suppl 18s):15506.
7. M.E. Gore, S. Hariharan, and C. Porta et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases Cancer 117 2011 501 509
8. J. Medioni, O. Cojocarasu, and J.L. Belcaceres et al. Complete cerebral response with sunitinib for metastatic renal cell carcinoma Ann Oncol 18 2007 1282 1283
9. R. Simon Design for efficient clinical trials Oncology (Williston Park) 3 1989 43 49
10. Verma J, Jonasch E, Allen PK, et al. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol doi:10.1097/COC.0b013e31825d59db, Published online August 13, 2012.
11. Z.D. Lim, A. Mahajan, and J. Weinberg et al. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy Am J Clin Oncol 36 2013 258 260